Home

Insights

Morepen Laboratories Ltd P/E Ratio

Morepen Laboratories Ltd P/E Ratio

download
stocks purchased

₹ 1.8 Cr

Volume transacted

stocks purchased

332.6 K

stocks traded

Image

Morepen Laboratories Ltd

NSE: MOREPENLAB

PE

24.6

Last updated : 13 Jun 05:03 AM

Key Highlights

    The P/E Ratio of Morepen Laboratories Ltd is 24.6 as of 13 Jun 05:03 AM .a1#The P/E Ratio of Morepen Laboratories Ltd changed from 27 on March 2019 to 33.8 on March 2023 . This represents a CAGR of 4.59% over 5 years. a1#The Latest Trading Price of Morepen Laboratories Ltd is ₹ 52.47 as of 12 Jun 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.7 to 27.7 in 5 years. This represents a CAGR of -0.71%a1# The PE Ratio of Automobile industry is 11.3. The PE Ratio of Finance industry is 21.7. The PE Ratio of IT - Software industry is 28.9. The PE Ratio of Pharmaceuticals industry is 102.9. The PE Ratio of Retail industry is 142.7. The PE Ratio of Textiles industry is 7.2. In 2024a1#The Market Cap of Morepen Laboratories Ltd changed from ₹ 775.95 crore on March 2019 to ₹ 1312 crore on March 2023 . This represents a CAGR of 11.09% over 5 years. a1#The Revenue of Morepen Laboratories Ltd changed from ₹ 303.31 crore to ₹ 427.32 crore over 8 quarters. This represents a CAGR of 18.70% a1#The EBITDA of Morepen Laboratories Ltd changed from ₹ 15.46 crore to ₹ 52.62 crore over 8 quarters. This represents a CAGR of 84.49% a1#The Net Profit of Morepen Laboratories Ltd changed from ₹ 5.63 crore to ₹ 28.74 crore over 8 quarters. This represents a CAGR of 125.94% a1#The Dividend Payout of Morepen Laboratories Ltd changed from 0 % on March 2019 to 0 % on March 2023 . This represents a CAGR of 0.0% over 5 years. a1#

Open Demat Account

Lead form image

+91

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

*By signing up you agree to our terms & conditions

×

P/E Ratio Over Time

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

P/E Ratio Over Time

Period
Mar '1927
Mar '2012.7
Mar '2114.9
Mar '2217.2
Mar '2333.8

Fundamental Metrics

Market Cap

2,682 Cr

EPS

1.9

P/E Ratio (TTM) *

24.6

P/B Ratio (TTM) *

2.8

Day’s High

53.1

Day’s Low

49.35

DTE *

0.0

ROE *

11.4

52 Week High

56.35

52 Week Low

27.08

ROCE *

15.8

* All values are consolidated

* All values are consolidated

Image

Morepen Laboratories Ltd

NSE: MOREPENLAB

PRICE

52.47

3.20 (6.49%)

stock direction

Last updated : 12 Jun 15:30

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Morepen Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

Asset Value vs Market Value

Market Value

2,366

Asset Value

766

2.1 X

Value addition

* All values are in Rupees

PE Ratio Over Market Cap

Key Valuation Metric

Earnings

96 Cr

24.6 X

PE Ratio

Market Cap

₹2365Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio

PS Ratio

PB Ratio

Earnings

96 Cr

24.6 X

PE Ratio

Market Cap

₹2365Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Morepen Laboratories Ltd PE Ratio Calculation

  • The Price-to-Earnings (PE) ratio, also known as the P/E Ratio, is a fundamental financial metric used to assess the valuation of a company's stock in relation to its earnings performance. For Morepen Laboratories Ltd, the PE Ratio is calculated as follows:

P/E Ratio

=

Market Capitalization

Net Income

  • Given the current market conditions, Morepen Laboratories Ltd's Share Price stands at 52.47. The Earnings per Share (Diluted) for the trailing twelve months (TTM) ending in 2024-06-12T00:00:00 is 1.88. Substituting the values into the formula, PE Ratio becomes as follows: PE Ratio = 52.47/ 1.88= 24.62.

P/E Ratio

=

Stock Price

Earning Per Share

  • This indicates that Morepen Laboratories Ltd's stock is trading at approximately 24.62 times its earnings per share for the trailing twelve months. Alternatively, the PE Ratio can also be computed using the company's overall financial performance: PE Ratio = Market Cap / Net Income. Where Market Cap represents the total market capitalization of the company, and Net Income signifies the total earnings after expenses and taxes.

Understanding Morepen Laboratories Ltd’s PE Ratio (BSE: MOREPENLAB)

    The Price-to-Earnings (PE) ratio, used to assess Morepen Laboratories Ltd's stock (BSE: MOREPENLAB), indicates how many years it would take for the company to earn back the stock price. If a company earns ₹2 per share annually and its stock trades at ₹30, the PE ratio is 15, signifying a 15-year payback period assuming steady earnings. Earnings fluctuate, affecting the payback period, Growing earnings shorten the recovery time while declining earnings extend it. Shareholders favor shorter payback periods, preferring lower PE stocks. Among stocks with the same PE ratio, faster-growing businesses are preferred. A company with losses makes the PE ratio meaningless. Peter Lynch introduced the PEG ratio to compare stocks with different growth rates, dividing the PE ratio by the growth rate. A company is considered fairly valued when its PE ratio matches its growth rate. The PE ratio, applicable across industries, measures stock valuation based on earnings power. It indicates how quickly an investment can be recouped. Unlike the PB ratio, which assesses valuation based on the balance sheet, the PE ratio focuses on earnings. Overall, the PE ratio provides insights into stock valuation, aligning with investors' preference for faster returns.

×

Market Cap Over Time

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Market Cap Over Time

Period
Mar '19776
Mar '20429
Mar '211446
Mar '221749
Mar '231313

* All values are a in crore

×

Revenue Over Time

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Revenue Over Time

Period
Jun '22303
Sep '22404
Dec '22350
Mar '22367
Jun '23403
Sep '23425
Dec '23449
Mar '23427

* All values are a in crore

×

EBITDA Over Time

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

EBITDA Over Time

Period
Jun '2215
Sep '2230
Dec '2222
Mar '2219
Jun '2329
Sep '2337
Dec '2355
Mar '2353

* All values are a in crore

×

Net Profit Over Time

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Net Profit Over Time

Period
Jun '226
Sep '2216
Dec '229
Mar '228
Jun '2315
Sep '2321
Dec '2332
Mar '2329

* All values are a in crore

×

Dividend Payout Over Time

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Dividend Payout Over Time

Period
Mar '190
Mar '200
Mar '210
Mar '220
Mar '230

* All values are a in %

About Morepen Laboratories Ltd

About Morepen Laboratories Ltd

    Morepen Laboratories Limited is an India-based pharmaceutical company. Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin. The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast. It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India. The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally. The company has developed a hi-tech Pharma complex at Morepen Village, Baddi (HP) on 60 acres of land that has various multipurpose pharma facilities for API & finished dosages and a Research Centre. The company was established in the year 1984. The company has filed 14 patents including 6 international PCT applications. The company has filed an international patent on a new amorphous form of the cholesterol-reducing drug Lipitor (Atorvastatin) that is the largest selling drug in the world. During the year 1991-1992, the company set up the new facilities for bulk manufacture of Cephalexin, 7 ADCA and CIMC Chloride at its existing location. During the year 1992-1993, the company started implementing its expansion plans for manufacture Cephalexin, 7ADCA, CIMC Chloride, Research and Development Block and Formulation unit. The company introduced two latest molecules, Ketrolac Tromethamine and Omeprazole. Also, the company also launched Loratadine and Cisapride. During the year 1993-1994, the company increased the installed capacity of Bulk Drugs from 162 MT to 245 MT. The company started the commercial production of Ketorolac Tromethamine, which is a potent analgesic. During the year 1994-1995, the company increased the installed capacity of Drugs & Drug Intermediates from 305 MT to 469 MT. During the year 1995-1996, the company successfully launched high value and high technology products namely, Cisapride & Loratadine. Also, the company launched herbal product namely Paclitaxel, an anti cancer drug. During the year 1996-1997, the company commissioned its own formulation unit, which gave a competitive edge to the company in terms of quality and cost efficiency. During the year 2000-2001, the company increased the installed capacity of Drugs & Drug Intermediates from 916 MT to 1170 MT. The company signed a joint venture with DiaMed AG of Switzerland, a proven international leader in blood group serology diagnostic products. Also, the company developed and launched wide range of contemporary, lifestyle oriented FMHG (Fast Moving Health Goods) Self Medication products. During the year 2001-2002, the company increased the installed capacity of Drugs & Drug Intermediates from 1170 MT to 1251 MT. Also, the company further increased installed capacity of Tablets / Capsules from 25080 Nos to 35000 Nos. During the year 2004-2005, the company developed the new polymorphic from V1 and field patent in 33 countries and in the same year, the company started finalizing marketing partner for filing ANDA's for the molecule. During the year 2005-2006, the company made 52 DMF filing across ten European countries for six products. Also, the company broadened its offering by introduced new product like Ducal, Rythmix, Montelast, Alcoflam, Levopen, Moezole, and Cefpen-S. During the year 2006-2007, the company improved its presence in the key market of South East Asia, Africa & Australia. During the year, the company acquired more than fifty new prospective customers in Korea, Japan, and Taiwan. During the year, the company started of OTC formulation under the umberalla brand 'Dr. Morepen'. During the year 2007-2008, the company made the tie ups with several new business segments. Marketing alliance with World leaders like lmmucor, USA (for immuunohematology system & consumables), Teco Medical Instruments, Germany (for coagulation system & consumables), InTec INC. (for ELISA Kits), Access Bio, USA (for Rapid Malaria Kits), helped the diagnostics division to make deeper inroads into both the consumer market and the blood bank and laboratory segment. In 2010, it launched Cardia Division for Diabetic and Cardiac products. In 2015, it started personal Grooming Division with brand GUBB USA. In 2019, it launched APIs for many anti-diabetic molecules. The Company launched 'IntebactImun' in boosting immunity of adults and kids in 2023. It started manufacturing two more products viz., Blood Pressure Monitors and Pregnancy Testing Kits in 2023.

Morepen Laboratories Ltd News Hub

News

Morepen Laboratories schedules board meeting

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 21 Ma...

Read more

15 May 202413:46

News

Morepen Laboratories EGM scheduled

Morepen Laboratories announced that an Extra Ordinary General Meeting (EGM) of the Company...

Read more

26 Feb 202410:28

News

Morepen Laboratories to convene board meeting

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 22 Fe...

Read more

19 Feb 202420:02

News

Morepen Laboratories to conduct board meeting

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 31 Ja...

Read more

25 Jan 202413:49

News

Morepen Laboratories to hold board meeting

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 2 Nov...

Read more

27 Oct 202315:19

News

Morepen Laboratories to hold AGM

Morepen Laboratories announced that the Annual General Meeting (AGM) of the company will b...

Read more

06 Sep 202317:35

Product Composition by Percentage (Revenue)

FAQs for PE of Morepen Laboratories Ltd

What is Morepen Laboratories Ltd current share price?

The current market price of Morepen Laboratories Ltd as of June 13, 2024 is ₹52.47.

What is Morepen Laboratories Ltd's market cap?

Morepen Laboratories Ltd's market capitalisation stood at ₹2,365 Cr as of June 13, 2024

What are Morepen Laboratories Ltd's total net assets?

According to Morepen Laboratories Ltd's most recent financial filings, the company's net assets total ₹765.7 Cr.

Is Morepen Laboratories Ltd making a profit or loss?

Morepen Laboratories Ltd's net Profit as of June 13, 2024 is close to ₹96 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199